Cervix Cancer Clinical Trial
Official title:
The Prognostic Value of Conization and Negative HPV Typing After Conization Prior to Surgical Intervention in Adenocarcinoma in Situ and Early Stage Cervical Cancer
In women with cervical cancer -Squamous cell carcinoma, Adeno carcinoma, Adeno-squamous carcinoma or AIS we want to examine prospectively: 1. Examine if negative HR-HPV after conization to the HR-HPV the women had before conization has a high prognostic value for no residual tumor in the final pathology. 2. To examine if conization in women with cervical tumor up to Stage I B 2 (FIGO 2018) is corelated with better prognosis.
The treatment of invasive cervical cancer is tailored according to the FIGO recommendations. The standard treatment for women with early-stage, (IA2-IB1) cervical cancer is simple or Radical Hysterectomy (RH) and in women with Adenocarcinoma in Situ hysterectomy is recommended when they finish their fertility program .A Few studies describe that conization before Radical Hysterectomy in women with cervical cancer stage I B 1 ( tumour up to 4 cm according to FIGO 2009 ) , are in correlation with better prognosis , Bizzari describe women that had conization before RH had better 5 year survival. Uppal report that those women have less recurrence, OR of 0.4 compared with women without conization. Chacon summarize SUCCOR study, a multi center study that collected data about 374 women with cervical cancer Stage I B 1 according to FIGO 2009 -tumour up to 4 cm .187 women had conization before RH and 187 had RH without conization. Women that had conization had 65% less recurrence 'and 75% les mortality. Several studies have explored the possibility of a less aggressive approach for cervical cancer patients with low-risk early-stage disease who wish to preserve fertility. The parameters that were investigated were: the depth of invasion, tumour diameter, lymph node status positive margins in conization, positive Endo Cervical Curettage (ECC) and lymph-vascular space invasion. Those parameters have a low sensitivity and between 50-65% of women who had RH had no residual tumour in the final pathology. Schmeler describe that woman who had conization before RH in 97.5% had no residual tumour. A study of 92 women with cervical cancer and Adeno Carcinoma In situ (AIS) that short time after conization were negative to High-Risk HPV (HR-HPV) they had before the conization in 95% there was no residual tumour in the final pathology, or during the follow up. To our knowledge there is no prospective study that examined the the prognostic value of Conization and negative HR- HPV typing after Conization prior to surgical intervention in Early-Stage Cervical Cancer and Adenocarcinoma in Situ. Aim: In women with cervical cancer -Squamous cell carcinoma, Adeno carcinoma, Adeno-squamous carcinoma or AIS we want to examine prospectively: 1. Examine if negative HR-HPV after conization to the HR-HPV the women had before conization has a high prognostic value for no residual tumour in the final pathology. 2. To examine if conization in women with cervical tumour up to Stage I B 2 (FIGO 2018) is corelated with better prognosis. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04067882 -
Validation of the Genetic Signature 354849 as a Prognostic Method
|
||
Completed |
NCT00329589 -
A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients
|
Phase 1 | |
Recruiting |
NCT05743517 -
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
|
N/A | |
Completed |
NCT05234112 -
Prevention and Screening Towards Elimination of Cervical Cancer
|
N/A | |
Completed |
NCT04258553 -
Thiol Disulfide Balance in Cervix Cancer
|
||
Completed |
NCT03956498 -
Impact of a Sexological Follow-up on the Sexual Function in Patients With Cervix or Vaginal Cancer Treated by Radiotherapy and Brachytherapy
|
N/A | |
Active, not recruiting |
NCT04357873 -
Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations
|
Phase 2 | |
Completed |
NCT00379743 -
Partnership for Healthy Seniors
|
N/A | |
Completed |
NCT00509444 -
Cancer Prevention and Treatment Among African American Older Adults: Treatment Trial
|
Phase 3 | |
Recruiting |
NCT06022029 -
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
|
Phase 1 | |
Recruiting |
NCT06116019 -
Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)
|
||
Completed |
NCT04072913 -
Matrix Metalloproteinases and Human Papillomavirus in Dysplasias and Cancers of the Cervix
|
N/A | |
Active, not recruiting |
NCT06452004 -
Validation of Artificial Intelligence as Decision Support System in VIA (PRESCRIP-TEC)
|
N/A | |
Recruiting |
NCT04651127 -
Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT06010875 -
A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT02552121 -
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02001623 -
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02997553 -
Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery
|
Phase 3 | |
Terminated |
NCT02233387 -
PET CT With HX4 in Cervix Cancer
|
Phase 2 | |
Completed |
NCT01766284 -
Study of the Diagnostic Efficacy of "Real Time" Niris 1300e Optical Coherence Tomography (OCT) Imaging System in the Management of Pre-invasive and Invasive Neoplasia of the Uterine Cervix
|
N/A |